Biocardia, Inc. (BCDA) - Form 8-K Summary
Business Context and Reporting Period
Biocardia, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 12, 2026. The filing serves to announce the company's financial results for the quarter ended June 30, 2026. The company's common stock trades on the Nasdaq Capital Market under the symbol BCDA.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. It solely references the issuance of a press release containing the quarterly results.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full announcement.
- Confirm if the company provided updated full-year 2026 financial guidance in the press release.